Dive Brief:

CVS has agreed to pay almost $38 million to settle allegations that its pharmacies overcharged the government for insulin pens over a decade, putting to bed a Department of Justice lawsuit and several whistleblower cases over the claims.

From 2010 through 2020, CVS pharmacies refilled insulin products too early, dispensed more than patients needed and falsely underreported how much insulin its pharmacies dispensed to avoid detection, according to the DOJ.

Roughly $25 million of the settlement will be paid to the U.S. government, with the remainder split between various states. CVS, which did admit culpability as part of the deal, said in a statement to Healthcare Dive that it was glad to put the matter behind it.

Dive Insight:

Insulin pens are a commonly used tool for diab

See Full Page